News Hub | News Direct

Big and Growing Need for Senior Care: Empowering Family Caregivers to Get the Supportand Guidance They Deserve

YourUpdateTV

November marks National Family Caregivers Month, a time to bring attention to the challenges faced by those caring for aging parents. Recently, Tatyana Zlotsky, President of A Place for Mom (APFM), conducted a satellite media tour to share vital insights and tips for family caregivers navigating the world of senior care. A video accompanying this announcement is available at: https://youtu.be/dUjQA6H_26Y There is a big and growing need for senior care, as the number of seniors is rapidly increasing and is projected to reach over 80 million by 2040. Today, 41 million Americans are unpaid caregivers for seniors, most often the adult daughter or son of their aging parents. As the senior population grows, family caregivers face serious challenges. A Place for Mom issued its new State of Caregiving Survey, showing that an overwhelming majority or caregivers are physically, mentally, and financially at risk. 82% have had to make sacrifices to provide adequate care. Nearly all (96%) reported being emotionally drained, with more than half feeling this way often or all the time. And 75% who were employed prior to assuming the caregiver role said they have less time to focus on work or have had to quit their jobs altogether to provide care. “These findings reveal some of the hard truths being faced by caregivers as they struggle to care for their aging parents and loved ones,” said Zlotsky. “Navigating the process of finding the most suitable senior care is not easy. There are three important things to consider – care needs, costs, and lifestyle.” First is care needs. Zlotsky shared that as seniors face a variety of physical and mental challenges, they require more and more assistance with their Activities of Daily Living. A Place for Mom finds that nearly all seniors they work with need some daily support, and more than 40% need extra help associated with dementia. The second is costs. “Families need help to better understand senior living costs in their area and options on how to pay,” said Zlotsky. At A Place for Mom, two-thirds of the families they work with have shared that they do not feel prepared when it comes to senior care costs and need help to better understand options and how to pay. “Lastly, families want to find a place where their parents will feel right at home -- a warm environment that helps them experience joy and feel a sense of community,” said Zlotsky. “This is where amenities and activities play an important role in helping mom or dad with the transition.” A Place for Mom has a team of senior living advisors who help caregivers navigate this journey end to end, all at no cost to families. “We start with a simple but very important question: tell us about your mom, dad, aunt, or uncle,” said Zlotsky. The expert advisors then gather critical information ranging from mobility, medication, and bathing assistance to mom’s favorite meals and activities. They then match those needs with preferred options and budget in order to make personalized recommendations for home care or senior living options to best assist the family. For senior living specifically, A Place of Mom also serves as a concierge to help families set up tours, understand feedback, and support the moving process. Special benefits and resources for veterans and their families: There are more than 8 million veteran seniors in the U.S. And at A Place for Mom – the veteran community is critically important. In fact, more than 30% of the families A Place for Mom helps are veteran families. “Veterans and their spouses may qualify for the VA Aid & Attendance benefit to help pay for senior care,” said Zlotsky. However, A Place for Mom’s survey revealed that more than two-thirds of veteran families don’t know how to access this monetary benefit or even understand it. A Place for Mom expert advisors are knowledgeable about VA benefits for senior care and help families understand what benefits are available. Their advisors’ expertise has helped families secure more than $8 million in financial aid annually. To expand their impact and help more veteran seniors and their families, A Place for Mom is joining forces with USAA, the leading veterans organization for financial resources, with over 13M members. Visit aplaceformom.com to learn more about A Place for Mom’s services and connect with a local expert advisor. About Tatyana Zlotsky Tatyana Zlotsky is the President of A Place for Mom, Inc., the leading online platform connecting families searching for senior care with a team of expert, local advisors providing insight-driven, personalized solutions. In this role, Tatyana leads the sales and marketing teams and is responsible for delivering on the company’s mission to enable caregivers to make the best senior living decisions. Since joining, Tatyana has served in various leadership roles at A Place for Mom and has successfully helped to transform the brand and overall family experience, which helps over 300K families per year. Tatyana joined A Place for Mom from American Express, where she spent nine years driving digital transformation as the VP/GM of Acquisition and Digital Innovation and was responsible for driving revenue growth in the U.S. Small Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 07, 2023 10:42 AM Eastern Standard Time

Video

Augmented Reality (AR) in the Classroom: Snap’s AR technology offers endless possibilities for creativity, engagement, and exploration.

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/QEuZ5YDnkRQ Through the magic of augmented reality (AR), students can learn in an immersive and flexible environment no matter where they are, helping them to better understand and engage with complex STEM concepts. Research shows that using virtual reality learning can deepen student comprehension through interactivity, greater context to the world, and a sense of scale and proximity that might not otherwise be possible. Snap’s AR technology offers endless possibilities for creativity, engagement and exploration. In traditional online learning environments, over half of students abandon their STEM courses before completion. To fill this gap, AR can aid in presenting complex concepts in a more tangible 3D format that empowers students to achieve their best. Through a partnership with Snap, Inspirit is hoping to make STEM learning more interactive and engaging for all students through their digital platform, the Innovative Learning Hub. Inspirit is creating 25 more Lenses powered by Snap AR focused on STEM curriculums that will be rolled out to at least 50 schools nationwide next school year. This exciting partnership was the focus of a nationwide media tour featuring Sophia Dominguez, the Director of AR Platform Partnerships & Ecosystem at Snap and Amrutha Vasan is the Co-Founder and COO of Inspirit include: Topics that they discussed during the media tour included: How augmented reality can supplement learning in the classroom. Ways that Snap’s AR technology offers endless possibilities for creativity, engagement and exploration. Partnership between Snap and Inspirit to bring immersive AR learning technology to classrooms to help revolutionize the way students learn. To learn more visit inspiritVR.com Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 07, 2023 09:47 AM Eastern Standard Time

Video

From Coal To Renewables: Altius Minerals

Benzinga

By Faith Ashmore, Benzinga Altius Minerals Corporation (OTCQX: ATUSF) (TSX: ALS), a Canadian diversified royalty company, is positioning itself strategically in the energy sector by transitioning from thermal coal to renewable energy royalties. This shift not only aligns with the global push towards decarbonization but also reflects the economic advantages of renewable energy on the grid. Altius Minerals acquired its first portfolio of royalties (after buying a single royalty in 2003) in late 2013. The portfolio included royalties on Canada’s world-leading potash mines in Saskatchewan, but the seller of the portfolio bundled the potash royalties with coal royalties on Alberta thermal coal mines. In 2015, both the Alberta and Canadian federal governments made announcements to significantly accelerate the phase-out of coal-fired electricity. This meant that mines (and Altius’s associated royalty) that were originally expected to run until 2055 received a government mandate to end by 2030. This represented a significant loss of potential royalty revenue to Altius – but also caused management to evaluate how best to evolve as a company. Altius recognized the need to divest from thermal coal and seize the opportunities presented by the growing renewable energy industry, and the company has taken an active stance in an industry that is often criticized for its contribution to climate change. The company’s move towards renewable energy was accelerated in 2019 when Altius acquired Great Bay Renewables, a private U.S. renewable energy company, to form a renewable energy royalty company. In 2020, Altius attracted prominent private equity player Apollo as a joint venture partner in its renewable energy business. This partnership signaled the growing interest and confidence in the renewable energy sector. Subsequently, in 2021, Altius successfully completed an initial public offering (IPO) for its renewable energy royalty vehicle, now known as Altius Renewable Royalties (OTCQX: ATRWF) (TSX: ARR). Altius is a royalty company that, unlike most of its competitors, has very little gold royalty exposure. Although gold has properties that make it uniquely adaptable for uses including medical and technology applications, its main demand source is jewelry and coins. Contrast that with copper, which, along with potash, makes up Altius’s main exposures. Altius has always pursued large, global end-use markets that address global sustainability problems. Most of the royalty revenue comes from potash, electrification battery metals and iron ore for green steel, along with their core holding in subsidiary ARR. These markets align with multiple UN sustainable development goals, such as eradicating poverty, ensuring renewable energy, responsible procurement and more. This strategic focus aligns with the values of stakeholders who believe in these goals. As a publicly listed company, ARR currently holds 33 royalties on wind, solar and soon-to-be battery storage projects in the United States. This extensive portfolio potentially positions ARR as a key player in the renewable energy royalties industry. Additionally, ARR has a robust 15 GW pipeline, showcasing its potential for future growth and expansion. The market for renewable energy royalties could be massive. With the increasing global focus on transitioning from fossil fuels to clean energy sources, investments in wind, solar and other renewable energy projects are expected to soar. According to Allied Market Research, the global renewable energy market was valued at $881.7 billion in 2020 and is projected to reach $1.9 trillion by 2030. Renewable energy royalties, in particular, have recently emerged as a growing segment of the renewable energy industry. As countries and corporations prioritize renewable energy to combat climate change and achieve sustainability goals, the demand for investments in this sector will likely continue to grow. Altius Minerals, with its focus on diversified minerals royalties, recognized this emerging market trend and strategically made its foray into the renewable energy sector. The potential size of the renewable energy royalties industry is expected to be larger than the scope of Altius Minerals itself. The massive investments in clean energy projects worldwide, coupled with the growing number of companies and investors involved in renewable energy royalties, indicate that the market has significant potential for expansion. Altius Minerals' strategic shift from coal royalties to renewable energy royalties through the formation of ARR demonstrates the company's adaptability and foresight in capitalizing on the potentially shifting landscape of the energy sector. With its IPO and an extensive portfolio of wind, solar and soon battery storage royalties, ARR seems well-positioned to benefit from the growing demand for renewable energy as the global transition to clean energy continues to gain momentum. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 07, 2023 09:00 AM Eastern Standard Time

Inaugural Women in Work Summit Focusing on Women’s Health at Work to take place on November 9th, 2023

1BusinessWorld

The Women in Work Summit, Founded by Intuitive Events US, will take place at the Edison Rooftop on November 9th, 2023. It will bring together business leaders, HR practitioners and clinical experts from across all industry sectors who will share their expertise and experience around women’s health and its impact on workforce participation - and what businesses can do to support women at all critical life and health stages. The Statistics: 55% of employees struggling with fertility say they’re not getting the support they need from their employers (Maven Clinic). 17 percent of women have quit a job or considered quitting due to menopause symptoms (Biote Women in the Workplace Survey, 2022) and failure to retain talent costs US businesses one trillion dollars a year according to a Gallup report. Studies by McKinsey & Company find that companies with more diverse workforces perform better financially, with a direct correlation identified between a diverse workforce and higher profits. McKinsey has found that companies with more than 30% female executives tended to outperform companies with 10% to 30% female leaders, and those companies outperformed companies with fewer or no women executives. (McKinsey, 2022) Speakers at the event include C-Suite executives, leaders, HR practitioners, and high profile personalities including Naomi Watts, Actor and Founder of Stripes; Mariella Frostrup, Journalist and Co-Founder of Menopause Mandate, Miriam Warren, Chief Diversity Officer, Yelp; Lucy Perez, Senior Partner, McKinsey, and Company; Jennifer Remling, Chief People Officer, WPP; Stephanie Kramer, CHRO, L’Oreal; Keith Lieberthal, Regional Head (Americas), Hakluyt; Carly Pierpoint, Managing Director, JP Morgan; and Ramin Beheshti, President & Co-Founder, The News Movement. “Disparities in health outcomes between different genders are more than just a statistical anomaly; they reflect a broader societal issue where women often receive suboptimal healthcare compared to men. This spans from reproductive health concerns to the management of life transitions such as pregnancy and menopause. The interplay between women’s health and their presence in the labor market cannot be overstated. It’s incumbent upon employers to step up and integrate comprehensive health strategies into the workplace. Absent strong policies and a culture that upholds these values, the repercussions are clear: a loss of valuable talent and a negative impact on the organization’s financial health. I am so pleased to acknowledge the commitment of our collaborators at this Summit. Their alignment and dedication to transforming the workplace into an inclusive environment for all genders is commendable. They are at the forefront, providing innovative solutions to support employees during pivotal moments in their lives. And I am grateful to them for taking the time to share their learnings and best practices, said Melissa Ashley, Co-Founder. All news and content distribution in partnership with News Direct. Intuitive Events US: Organizers of the MenoChannel and the Women in Work Summit. Proudly bringing together leading experts in their fields to support those who need help navigating health and wellbeing across life stages. Intuitive Events US also run Menopause Mandate US, the campaign group to keep menopause high on the corporate, media and political agenda. Women in Work Summit: a one-day face-to-face event dedicated to creating equitable workforces to drive business growth. Tickets are available here https://www.wiwsummitus.com REGISTER HERE FOR YOUR PRESS PASS: STRICTLY LIMITED AND BY INVITATION ONLY For Information: Contact melissa.ashley@intuitiveevents.co.uk Contact Details Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

November 06, 2023 11:36 AM Eastern Standard Time

Image

Tomorrow in New York, A Seminar Opens the Gateway to Brazil’s Robust Market Opportunities

1BusinessWorld

The Brazilian-American Chamber of Commerce, in collaboration with the Instituto Brasileiro de Desenvolvimento de Relações Empresariais Internacionais (IBREI), is set to host an influential breakfast seminar that promises to unpack the labyrinth of opportunities in the flourishing Brazilian market. Titled "Opening the Doors to the Brazilian Market," this event stands as a pivotal rendezvous for business leaders aiming to penetrate or expand their footprint in South America's largest economy. https://brazilcham.com/event/opening-the-doors-to-the-brazilian-market/ Scheduled to convene at the Brazilian-American Chamber of Commerce's headquarters in Manhattan, the event is engineered to offer a comprehensive overview and insider knowledge of Brazil's diverse and intricate market. It will feature a cadre of experts and seasoned practitioners, providing attendees with the foresight needed to navigate and excel in a complex, yet rewarding business landscape. The first panel, moderated by James Rosenstein of 1BusinessWorld, promises an in-depth look at Brazil's economy, discussing entry strategies, sectorial overviews, and emerging opportunities. Notable speakers such as Luiz Flávio Cordeiro and Ramon Fernandez Aracil Filho will connect via Zoom, offering their expertise remotely, while Maurício Prazak will provide his insights in person. In the second panel, moderated by Jeff Levy, a senior figure in business development at 2H Software and advisor at 1BusinessWorld, the focus will shift to the tactical side of operations within Brazil. Attendees will be treated to case studies of U.S. companies that have successfully planted their flags in Brazilian soil, with valuable lessons on navigating the legal and regulatory challenges presented by the Brazilian business environment. “The Brazilian market is ripe with opportunity, yet it presents unique challenges that can be daunting for the uninitiated," says Maurício Prazak. "This seminar is tailor-made to equip business leaders with the knowledge and connections necessary to turn these challenges into profitable ventures." The event is a must for C-suite executives, entrepreneurs, and business developers looking to engage with one of the world's most vibrant economies. It's an opportunity to not only gain valuable insights but also to network with like-minded professionals and potential partners. The breakfast seminar underscores the chamber's commitment to fostering bilateral commercial ties and is a testament to the robust economic linkages that bind the U.S. and Brazil. “This seminar is more than just an event; it's a beacon for U.S. companies aiming to understand and succeed in Brazil,” said a spokesperson for the Brazilian-American Chamber of Commerce. “It embodies our mission to facilitate bilateral commerce and investment, and offers an exclusive platform for strategic engagement.” As international market dynamics continue to evolve, the seminar represents a timely and strategic conclave for those looking to diversify their international portfolios and align with the pulse of Brazil's economic prospects. Prospective attendees are urged to register early due to limited seating. The details of the seminar, including registration information and agenda, can be found on the Brazilian-American Chamber of Commerce’s website. Venue and registration information: Brazilian-American Chamber of Commerce 485 Madison Avenue, Suite 401 New York, NY, 10022 https://brazilcham.com/event/opening-the-doors-to-the-brazilian-market/ This in-person event is not only an investment in knowledge but also an invaluable opportunity to network with those who are shaping the future of U.S.-Brazilian trade relations. All news and content distribution in partnership with News Direct. The Brazilian-American Chamber of Commerce, Inc., based in New York City, is an independent, not-for-profit business membership organization. A non-governmental association, the Chamber’s mission is to promote trade, investment, and cultural ties between the two nations and to help develop closer ties between the business communities of both nations. The Chamber acts as a host to bring together audiences to learn about the latest developments and opportunities in Brazil. It is a source of information for both Americans and Brazilians regarding the latest business practices and facilitates interpretation and understanding of Brazil for the international business community. Brazilian-American Chamber of Commerce The Instituto Brasileiro de Desenvolvimento de Relações Empresariais Internacionais (IBREI) is a non-profit civil association that brings together individuals and companies, in different countries, aiming at national development. Its mission is to build bridges between professionals, companies and institutions, both public and private, improving the quality of the national and international business environment. Instituto Brasileiro de Desenvolvimento de Relações Empresariais Internacionais About 1BusinessWorld: 1BusinessWorld is a global business ecosystem, network and marketplace that provides entrepreneurs, business owners and professionals with the information, tools, resources and connectivity needed to succeed throughout their company’s growth journey, toward a better business world. Our vision is based on the reality that we live, work and do business in one global interconnected business environment, and hence our motto: “One World, One Business World”. Our mission is to encourage and support global communication and collaboration among entrepreneurs, professionals, and businesses. 1BusinessWorld Contact Details 1BusinessWorld Media Enquiries +1 212-220-6677 info@1businessworld.com Company Website https://1businessworld.com

November 06, 2023 11:23 AM Eastern Standard Time

Image

Minuteman Press Franchise Owner Nil Patel Talks Leaving Corporate World, Celebrates Grand Opening in Solon, Ohio

Minuteman Press International Inc

After working in corporate finance, Nil Patel was looking for a career change. He shares, “I previously graduated from the University of Cincinnati with a bachelor’s degree in finance. After 8 years in the corporate world, I realized it was not for me. I wanted to be part of a company that helps others and be somewhere I can feel gratitude from the work I do!” Nil found what he was looking for in June of 2023 when he purchased the Minuteman Press franchise in Solon, Ohio. He explains, “I chose Minuteman Press because I wanted to be a part of a small business that has potential to grow and help other business thrive around me. The training and support from Minuteman Press International has been great! My RVP Rich DeRosa in particular has been extremely helpful and professional.” In September of 2023, Nil celebrated his grand opening; Minuteman Press in Solon is located at 33528 Aurora Road, Solon, OH 44139. Nil shares, “The community of Solon is a diverse blue-collar town where people are proud of the work they do! Our grand opening was a huge success. It was put together by the Solon Chamber of Commerce and I received extra help from my girlfriend and parents to really bring it all together. I’m excited to continue to serve and be a contributing member of the Solon community.” A few months into owning the business, Nil is happy with his progress as a business owner. He says, “I explain to clients that Minuteman Press in Solon is a full-service design, print, and marketing center serving the entire business community from small businesses to Fortune 500 companies. Our client base and business have been steady and we are growing.” Nil adds, “High-demand products that can help other local businesses/organizations grow are business cards, banners, flyers, and promo products – pens, calendars, koozies, flash drives, etc.” When asked about the industry and what he enjoys the most thus far, Nil answers, “Printing remains vital today because physical and digital advertising are both continuing to grow and this trend is going to continue.” He concludes, “Clients are looking for a healthy mix of both and I love that I can grow my business while helping others grow as well.” Minuteman Press in Solon, Ohio is located at 33528 Aurora Road, Solon, OH 44139. For more information, visit their website: https://minuteman.com/us/locations/oh/solon Learn more about #1 rated Minuteman Press franchise opportunities and read Minuteman Press franchise reviews at https://minutemanpressfranchise.com Contact Details Minuteman Press International Chris Biscuiti +1 631-249-1370 cbiscuiti@mpihq.com Company Website https://minutemanpressfranchise.com

November 06, 2023 10:00 AM Eastern Standard Time

Image

How IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The Past

Benzinga

By Ted Stavetski, Benzinga IN8bio Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company tackling one of society’s most pressing issues: cancer. Specifically, the company is focused on using the immune system to eliminate residual tumors, and currently has two clinical programs focused on leukemia and on glioblastoma, the deadliest type of brain cancer. IN8bio is pioneering a new approach using the immune system to tackle the deficiencies that plague most current cancer treatments. Alpha-beta T cell-based chimeric antigen receptor, or CAR-T therapies have shown remarkable results against some leukemias and myelomas. However, many of these CAR-T treatments have faced challenges against more difficult-to-treat leukemias, such as acute myeloid leukemia (AML) and solid tumor cancers. These cancers can be highly heterogenous, making them difficult to kill since they are often intertwined in healthy tissues, leading to unintentional toxicities and adverse events. In some cases, patients have even died. Fortunately, IN8bio may have found the solution to this problem. What Is “Cancer Zero?” IN8bio set out on a mission that it calls “Cancer Zero”, which co-founder and CEO William Ho describes as “the goal of pursuing the safe eradication of all tumor cells in patients fighting cancer.” In other words, the company aims to eliminate all cancer cells without destroying healthy cells. To achieve this, the company has developed advanced technologies using a specific subset of immune cells, or lymphocytes called gamma-delta T cells, in its DeltEx platform. Gamma-delta T cells are white blood cells whose job in the body is to be a first-responder and to determine safe and not-safe. They kill invading or dangerous cells and can call in reinforcements by recruiting and activating other immune cells. It was IN8bio’s co-founder, Dr. Lawrence Lamb, a clinical immunologist on a cancer ward treating patients with aggressive leukemias in the 1990s, who made the first observation that gamma-delta T cells are linked to greater survival in cancer patients. He spent the next 25 years figuring out how to expand, genetically engineer and manufacture gamma-delta T cells at scale and into a cancer therapy. In 2016, IN8bio was launched to take these gamma-delta T cell technologies into the clinic and today, Dr. Lamb is IN8bio’s Chief Scientific Officer. He leads a team of scientists and researchers dedicated to achieving the company’s mission of Cancer Zero. IN8bio’s DeltEx platform uses gamma-delta T cells that it believes are potentially safer and more effective at killing cancer cells than other therapies currently in development. The company has the capability to utilize autologous (from the patient), allogeneic (from a donor or “off-the-shelf”) and induced pluripotent stem cell (iPSC)-derived gamma-delta T cells. These cells can be expanded, activated and genetically engineered outside of the body to increase their numbers and to enhance their hunting and killing abilities. In one platform unique to IN8bio, its drug resistant immunotherapy (DRI) technology enhances gamma-delta T cells by genetically engineering them to be chemotherapy resistant. Chemotherapies have been a mainstay of front-line cancer therapy since World War II. While effective at shrinking a tumor and prolonging survival, they also kill white blood cells. As a result, microscopic residual tumors that are resistant to therapy often remain and result in relapse because of the weakened immune system. IN8bio’s DRI approach allows the simultaneous combination of chemotherapy with an immune therapy that may create synergies that allow the DRI gamma-delta T cells to recognize and eliminate the residual tumor cells while leaving healthy tissues alone. By targeting compartments of residual tumor cells, IN8bio’s DRI approach may achieve deeper tumor responses that can prolong survival. The company has already protected the DRI technology behind this process with issued patents around the world. IN8bio: Drugs In Clinical Development IN8bio has three therapies that are in varying stages of clinical development: INB-400: A phase 2 multi-center clinical trial for the treatment of newly diagnosed glioblastoma, or GBM ( NCT05664243 ). This trial has recently initiated enrollment at leading brain tumor centers across the United States following clearance of a company-sponsored investigational new drug application, or IND, by the U.S. Food and Drug Administration, or FDA. This program received Orphan Drug Designation (ODD) from the FDA in the spring of 2023 for targeting a significant unmet medical need, which offers potential incentives such as 7-year market exclusivity. INB-200: A phase 1 clinical trial at the University of Alabama at Birmingham using autologous, genetically modified DRI gamma-delta T cells for the treatment for newly diagnosed glioblastoma (UAB - NCT04165941 ). This program was one of only four central nervous system (CNS) cancer programs to have received an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the largest world-wide yearly gathering of cancer clinicians and researchers. At that time, the company released initial phase 1 data showing that 100% of treated patients have exceeded expected median progression-free survival. An additional clinical update is expected in November 2023 at the Society for Neuro-Oncology Annual Meeting (SNO), and long-term follow-up data is expected to be presented at medical meetings in the first half of 2024. INB-100: A phase 1 trial for the treatment of patients with high-risk leukemias undergoing haploidentical stem cell transplantation, or HSCT ( NCT03533816 ). The company presented a clinical update at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting in April 2023 that demonstrated 100% of evaluable patients (n=7) treated with INB-100 remained alive, progression-free and in durable complete remission (CR) as of April 21, 2023. Patients included high-risk AML patients and a patient with acute lymphoblastic leukemia (ALL) who had failed four prior lines of therapy, including CAR-T. All evaluable patients remained alive as of the last assessment and one patient had survived for three years. IN8bio has completed primary enrollment of the phase 1 clinical trial, with updated results expected at the American Society of Hematology (ASH) Annual meeting in December 2023. Topline long term follow ups are expected in 2024. To further its research, IN8bio recently opened a new 10,000-square-foot research & development (R&D) facility in Birmingham, Alabama. This state-of-the-art facility not only bolsters the company’s ability to advance its groundbreaking pipeline of gamma-delta T cell therapies, but also further taps into the advanced cancer research at the UAB, and other prominent institutes. Additionally, the company holds a total of 19 granted U.S. and international patents with many more still pending approval. This will help IN8bio protect its innovative new therapies from competitors as they proceed through clinical trials towards future commercialization. Cancer Immunotherapy Market IN8bio is tackling a large market. Grand View Research estimates that the global cancer immunotherapy market was worth approximately $115 billion in 2022 and is expected to grow at a compound annual growth rate of 8.7% from 2023 to 2030. Diving deeper, the American Cancer Society estimates that there will be 59,610 new cases of leukemia (and 23,710 deaths) in 2023, and the National Brain Tumor Society estimates that there were 13,400 new cases of glioblastoma in 2022. Despite being a lesser-known disease, awareness of glioblastoma is growing quickly. This is mainly due to the unfortunate, high-profile deaths of the President’s son, Beau Biden, and former U.S. Senator John McCain. One Step Closer Towards Cancer Zero IN8bio’s portfolio of cell therapies has the potential to offer a better treatment option for patients suffering from difficult to treat solid and liquid tumors such as AML and glioblastoma. The company’s primary advantage is its patent-protected platform gamma-delta T cell technologies, which it believes may allow it to better target cancer cells, getting deeper responses without hurting the patient’s healthy cells. The biotechnology company has had its foot on the gas pedal in recent years, boasting the following achievements: Two programs in phase 1, and enrollment has been initiated in its corporate-sponsored phase 2 trial at multiple sites across the U.S. A portfolio of preclinical programs in development including: iPSC derived gamma-delta T cells platform. iPSCs represent a significant step toward next generation approaches of cellular manufacturing for true allogeneic and potentially ‘off-the-shelf’ cellular therapies. INB-300, which focuses on addressing various solid and liquid tumors using a dedicated gamma-delta non-signaling CAR-T, or nsCAR, construct. These nsCAR constructs are designed specifically for the biology of gamma-delta T cells and allow IN8bio to potentially target tumor tissues while leaving healthy tissue alone. This could potentially create safer and more potent therapies. 19 granted patents for its technology. A brand new state-of-the-art R&D facility. $17 million in cash on hand, as of June 30, 2023, to help fund its operations and drug development. While the company is currently unprofitable – posting a net loss of $7.7 million for the three months ended June 30, 2023 – this is largely expected for biotechnology companies in the clinical development stage as they work to develop new drugs. However, IN8bio’s approach to business appears to be quite different in the biotechnology industry. The company reports it has been able to advance its clinical and preclinical programs by being extremely efficient with the capital raised, searching for innovative ways to advance their preclinical and clinical programs. Whereas IN8bio has successfully advanced multiple programs into phase 1 and 2 clinical trials while only having spent $76.5 million through 2Q23, a number of competing cell therapy companies have spent far more while showing similar, or less progress. Co-founder and CEO, William Ho has over 22 years of combined experience managing biotechnology companies, healthcare finance and investing, while co-founder and CSO, Lawrence Lamb has been in cellular therapy for three decades. They and the rest of the management team have the experience and know-how to effectively execute, manufacture, develop and advance the company’s growing portfolio of cancer therapies. With any luck, IN8bio will be able to achieve their mission of Cancer Zero, making cancer a thing of the past. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 06, 2023 09:00 AM Eastern Standard Time

Where Is Your Doctor Investing? Chances Are It Could Be DLP Capital – A Deep Dive Into The Returns Offered By The Firm’s Housing-Focused Funds

Benzinga

By Austin DeNoce, Benzinga Physicians, after years of intensive training and practice, are known for their rigorous and methodical approach when making decisions that impact their patients' health. This same attention to detail can often extend to their financial investments, and many are curious about where successful doctors invest their money. Treating patients, like investing, requires intelligence and patience. Among the myriad of investment choices available, DLP Capital emerges as an interesting choice due to its comparable ethos reflected in its broader vision of positively impacting society, and doctors seem to have taken notice – the company reports doctors have invested over $260 million in DLP Capital’s housing-focused funds. A Glimpse Into DLP Capital's Portfolio Since it was founded in 2006, DLP Capital has solidified its position in the investment landscape, earning a spot on the Inc. 5000 Fastest-Growing Companies list and retaining it for 11 consecutive years. The firm manages assets valued at over $5 billion, drawing support from a diverse pool of more than 2,600 investors. Owning and overseeing over 18,000 housing units, several of their funds have met or even surpassed their targeted returns. Through their varied endeavors, DLP Capital claims to have positively impacted more than 838,000 lives. Historical Returns: A Snapshot DLP Lending Fund: With a target annual return of 9-10%, this fund managed a 12.71% annual return as of September 30, 2023. As a private REIT emphasizing rental housing in high ownership-cost areas, it offers investors liquidity, a rigorous borrower vetting process and a 90-day redemption period without long-term constraints. Prioritizing investor returns, all preferred payouts are dispensed before any management fees, and invested capital retains a top-tier position, ensuring payment precedence over common equity participants. DLP Building Communities Fund: With an ambitious target of 11-13%, this fund achieved an annual return of 12.81% by the end of 2022. Designed as an evergreen private real estate fund, it focuses on developing new rental communities for attainable housing while providing a measure of protection against stock market volatility, consistent asset valuation for growth and flexible redemption options. All returns are prioritized to investors before any management fee is levied, ensuring their capital retains a preferred, high-priority position in all deals. DLP Preferred Credit Fund: This fund achieved a return of 10.52% in Q2 for 2023 on its 10-11% annual target, emphasizing insulation against rising interest rates and ensuring liquidity. By rigorously vetting borrowers and prioritizing loans to seasoned real estate sponsors, the fund ensures investors enjoy a preferred payment position and monthly returns before management fees, aligning the interests of DLP with its investors. Focusing on debt and preferred credit investments in the Sun Belt, its intent is to make a dent in America's affordable housing crisis, ensuring that rentals are attainable for working families. DLP Housing Fund: Perhaps the most eye-catching of the lot, DLP reports this fund saw an annual return of 27.04% by September 30, 2023, much higher than its annual target of 10-11%. By investing equity in multifamily rental communities (including manufactured housing and RV), the fund emphasizes both renter affordability and investor returns. The fund operates as an open-ended, private real estate venture focusing on long-term assets to yield enhanced returns. Investors not only benefit from tax advantages like depreciation offsets and 1031 tax-deferred exchanges, but they also enjoy flexible annual redemptions and a preferred position, guaranteeing payment priority over common equity investors. With returns like this, DLP may seem like a natural choice for many, but doctors are being attracted to DLP Capital for multiple reasons. The Attraction Of Passive Income One of the primary draws for busy professionals – such as those in the medical field – is the concept of passive income. They can enjoy the fruits of their investments without the daily demands of active engagement. DLP Capital's offerings, especially with its history of consistent returns, specifically aim to satisfy this demand for passive income – and doctors seem to find them particularly appealing. Impact Investing: Partnering With Doctors To Do Good Professionals like doctors frequently align their investment choices with societal benefits. Given the intrinsic desire among many in the medical profession to contribute positively to society, there's potential interest in DLP Capital, primarily due to its initiatives in affordable housing. Specifically, the DLP Housing Fund focuses on rental housing aimed at those with incomes near the area median. Likewise, the DLP Preferred Credit Fund and the DLP Building Communities Fund incorporate rental affordability into their strategies. Consequently, these funds combine financial objectives with addressing a relevant societal challenge. Exceeding Expectations DLP Capital has maintained a consistent investment record. Since its founding in 2006, there have been no reported capital losses for investors. Such reliable performance, alongside the size of potential returns, are important considerations for those evaluating investment options. Some of DLP Capital's funds have also achieved returns beyond their initial targets, reflecting reasonable success for some of its investment strategies. At the very least, their performance suggests a capacity to meet and occasionally exceed market expectations, though past performance is not a guarantee of future performance. Don Wenner, the CEO of DLP Capital, has played a significant role in the firm's direction. With over 16,000 real estate transactions amounting to more than $4 billion since 2006, his experience is extensive. Leveraging his experience, DLP's overarching mission includes both profit generation and broader goals to positively influence millions of lives. DLP Capital's Prognosis DLP Capital has positioned itself within the investment space by emphasizing passive income, societal impact and consistent returns – and successful professionals like doctors seem to be paying attention, with over a quarter of a billion invested by the medical community. The firm offers a comprehensive approach that integrates passive revenue streams, initiatives in affordable housing and a track record that reflects its strategy and performance over time. All returns aside, DLP Capital's alignment with affordable housing initiatives echoes the ethos of many in the medical profession and could be attractive to others, especially those seeking to yield a positive societal impact through their investments. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 06, 2023 09:00 AM Eastern Standard Time

Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System

Benzinga

By Jeremy Golden, Benzinga An estimated 609,820 people will die of cancer in the United States this year, according to the National Cancer Institute. Promising results from a 12-year-old clinical-stage biotechnology company have experts optimistic about the future of treating this deadly disease. With its proprietary Amphiphile or “AMP” platform, Elicio Therapeutics Inc. (NASDAQ: ELTX) has developed multiple cancer vaccine candidates that concentrate an array of different immunogens in the lymph nodes. ELI-002 is Elicio’s lead clinical program for Kirsten rat sarcoma (KRAS) driven cancers caused by a mutation of the KRAS gene. An “off the shelf” approach designed to stimulate an immune response against the seven KRAS mutations driving 25% of solid tumors, ELI-002 is currently being studied in AMPLIFY-201 – a phase 1 dose escalation study – and AMPLIFY-7P, a phase 1/2 study. In September, Elicio released new information about the vaccine candidates in its pipeline at the ninth AACR Special Conference on Pancreatic Cancer in Boston. The positive preliminary relapse-free survival (RFS) data from the ongoing AMPLIFY-201 study demonstrated an 86% reduction in risk of progression or death in patients with large T-cell responses induced by ELI-002 2P, a 2-peptide formulation designed to treat cancers driven by G12D and G12R mutations in KRAS. Despite the AMPLIYF-201 study not including a control arm, the median RFS of over 16 months is significantly longer than what has been seen in other studies of similar patient groups. “Patients with mutant KRAS cancers, particularly pancreatic and colorectal cancers, have a poor prognosis with limited treatment options when tumor DNA or protein biomarkers are detected after standard surgery and chemotherapy,” said Eileen M. O’Reilly, M.D., Winthrop Rockefeller Endowed Chair of Medical Oncology and Co-Director of Medical Initiatives at David M. Rubenstein Center for Pancreatic Cancer Research. “We are encouraged by the early data showing ELI-002 induced T cells can positively impact clinical endpoints including the risk of relapse and death in this study.” Targeting Immunogens To Lymph Nodes Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, which are located throughout the body on the lymphatic vessels at various intervals along the lymphatic routes. During the process of circulating throughout the lymphatic system, lymph fluid accumulates antigens and other biomolecules captured from the tissues. This fluid then drains into the lymph nodes, where it encounters T cells and B cells congregating together with antigen-presenting cells (APCs). Targeting the immunogens in the lymph nodes has been proven to result in tumor or pathogen-targeted immunity, including potent T cell and humoral responses, in preclinical trials. Alongside AMPLIFY-201, ELI-002 7P is currently being studied in AMPLIFY-7P, a phase 1/2 trial in patients with high relapse risk mKRAS-driven solid tumors. Designed to provide immune response coverage against seven of the most common KRAS mutations, the ELI-002 7P formulation increases the potential patient population for ELI-002 while possibly reducing the chance of bypassing resistance mechanisms. Moving forward in early 2024, Elicio Therapeutics plans to initiate a randomized phase 2 trial studying ELI-002 7P as a monotherapy in adjuvant PDAC patients. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

November 03, 2023 09:00 AM Eastern Daylight Time

Communications

Big and Growing Need for Senior Care: Empowering Family Caregivers to Get the Supportand Guidance They Deserve

Augmented Reality (AR) in the Classroom: Snap’s AR technology offers endless possibilities for creativity, engagement, and exploration.

From Coal To Renewables: Altius Minerals

Inaugural Women in Work Summit Focusing on Women’s Health at Work to take place on November 9th, 2023

Tomorrow in New York, A Seminar Opens the Gateway to Brazil’s Robust Market Opportunities

Minuteman Press Franchise Owner Nil Patel Talks Leaving Corporate World, Celebrates Grand Opening in Solon, Ohio

How IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The Past

Where Is Your Doctor Investing? Chances Are It Could Be DLP Capital – A Deep Dive Into The Returns Offered By The Firm’s Housing-Focused Funds

Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System